COVID-19 studies are enrolling.

covid 19 Vaccine Trial 
Those who qualify:*

  • Research Payment Up To $740

COMMENTARY: Cutting corners by fast-tracking a COVID-19 vaccine could be unsafe – National

Russia’s announcement that a fast-tracked COVID-19 vaccine is registered there, with plans for quick distribution in the general population this fall, is being condemned by scientists worldwide.

Findings from scientific studies of this vaccine, named “Sputnik V,” are not available. Large safety and efficacy trials are only now getting underway. But despite only two months of preliminary testing in people, Russian President Vladimir Putin called the vaccine “quite effective” and it’s received regulatory approval.

READ MORE: Russia clears coronavirus vaccine, insists it’s safe as scientists sound alarm

In other places, notably the United States, China and the European Union, even as researchers rush to develop vaccines, they continue to publish studies of these vaccines at a more measured pace than is happening in Russia.

Story continues below advertisement

As an epidemiologist who studies vaccine hesitancy and vaccine-preventable disease, I’m concerned about this news from Russia. After essential workers and high-risk groups are vaccinated, I would want to be among the first in line for an approved COVID-19 vaccine, but the medical research system must make sure any vaccine is safe and effective before distributing it to the population at large.

Clinical trials have a valuable role

Before any drug, vaccine or medical device is licensed for use in the general population, it needs to go through several rounds of large-scale testing. These studies are designed to make sure the intervention is safe and effective, and to understand what the appropriate dosage will be.

Under normal conditions, the research required to bring a vaccine to market can take decades. For example, before the HPV vaccine was licensed in the U.S. in 2006, a phase III clinical trial enrolled 18,644 participants in 2004-2005, a phase II clinical trial had enrolled 1,113 participants in 2000, and the laboratory studies that led to a vaccine candidate had been published in the early 1990s.

Story continues below advertisement

In the face of the coronavirus pandemic, scientists around the globe are focusing their efforts on developing a COVID-19 vaccine. They’re working at an unprecedented pace to move through the necessary clinical trials to end up with a safe and effective vaccine. One of the most time-consuming parts of clinical trials is enrolling participants, and pharmaceutical companies have sped up this process by lining up volunteers early, obtaining important baseline data from them even before a vaccine candidate is available.

3:32Health Matters: COVID-19 Vaccine

Health Matters: COVID-19 Vaccine
Problems if the vaccine is released too early

Trending Stories



Here’s what B.C. youth have to say about the province’s coronavirus spike



Ontario reports 81 new coronavirus cases, no additional deaths

Carefully conducted clinical trials are necessary to identify any problems with the vaccine. For example, studies of a new type of measles vaccine in the early 1990s found that it was detrimental to baby girls, and so it was never licensed to the general population. The existing measles or measles-mumps-rubella vaccine available in the U.S. and other countries is highly safe and effective.

Story continues below advertisement

It could also be that the vaccine is not effective in some categories of people. Phase I and II clinical trials have small sample sizes and may not include individuals from high-risk groups. For example, a recently published phase II clinical trial of a COVID-19 vaccine excluded obese people, those with chronic diseases and pregnant women. However, these are all groups that should be able to get the vaccine in the future. More studies, including phase III trials, are necessary to discover if the vaccine works in the general population. Preliminary results should be available by the end of 2020.

The concern is that by introducing the vaccine early, without adequate testing of safety, effectiveness and dosing, the population may be presented with a vaccine which is not safe or not effective, and with little information on which vaccine schedule is best.

Food and Drug Administration Commissioner Dr. Stephen Hahn has said the FDA will not “cut corners” in approving a COVID-19 vaccine in the U.S. despite an accelerated program, dubbed Operation Warp Speed.

In 1956, boxes of polio vaccine were rushed for delivery, but only after clinical trials concluded and it was approved by the FDA. Bettmann via Getty ImagesRushing to market

But is there ever an ethical reason to release a vaccine early, even without going through all phases of clinical trials?

Story continues below advertisement

Although it would be wonderful to get a vaccine into the population quickly, there could be substantial downsides if researchers and manufacturers cut corners. Imagine a vaccine that often had serious side effects that weren’t caught in small trials before it was widely administered.

An untested vaccine wouldn’t just harm the people vaccinated. If negative perceptions about the safety or efficacy of a COVID-19 vaccine spread throughout the population, it could limit how many people are willing to get the shot and perpetuate disease transmission.

READ MORE: Canada inks deals with Pfizer, Moderna for coronavirus vaccine candidates

Trust in vaccination programs is crucial. Russia, in fact, provides an important historical example. In the 1990s, trust in the country’s public health system rapidly decreased, and rates of diphtheria-tetanus-pertussis vaccination fell as a result. A large outbreak of diphtheria then spread through eastern Europe, leaving over 4,000 people dead.

Hasty rollout of a COVID-19 vaccine could prime people not only to not trust the COVID-19 vaccine, but also to doubt vaccination and public health systems as a whole.

Vaccinations should be developed by impartial scientists and evaluated by nonpartisan government officials. By cutting red tape, procedures can be prioritized and sped up, but they must not be skipped.

Abram L. Wagner, Research Assistant Professor of Epidemiology, University of Michigan

Story continues below advertisement

This article is republished from The Conversation under a Creative Commons license. Read the original article.





Source link

Share:

More Posts